Loading…
The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement
We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from...
Saved in:
Published in: | Texas Heart Institute journal 2013, Vol.40 (1), p.50-55 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 55 |
container_issue | 1 |
container_start_page | 50 |
container_title | Texas Heart Institute journal |
container_volume | 40 |
creator | Altintas, Garip Diken, Adem Ilkay Hanedan, Onur Yurdakok, Okan Ozyalcin, Sertan Kucuker, Seref Alp Ozatik, Mehmet Ali |
description | We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P < 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P < 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3568268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1315627660</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-1eddf7330b9ae24f7c83bfdfd91ac108bee981a425f90697d0f00bb43f445e9b3</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobk7_guTSm0I-2rTxQpDhVBjsYvNOKEl74ippU5O0sH9vYVP06sA573keeM_QnGZMJCIn7BzNSc5Jwniaz9BVCJ-EEM4ou0SzaSeEZHKO3nd7wFvnmw6vPEDtWrzdrDc4ROiihRBwbEIYAI_KjnCPQXl7wG6IlWshYGUieKycj011jGAPvVUVtNP_Nbowyga4Oc0Fels97ZYvyXrz_Lp8XCc9EyImFOra5JwTLRWw1ORVwbWpTS2pqigpNIAsqEpZZiQRMq-JIUTrlJs0zUBqvkAPR24_6BbqalJ7ZcveN63yh9Kppvx_6Zp9-eHGkmeiYKKYAHcngHdfA4RYtk2owFrVgRtCSTnNBMuFIFP09q_rV_JTKf8G9CB2Pg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315627660</pqid></control><display><type>article</type><title>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</title><source>PubMed Central</source><creator>Altintas, Garip ; Diken, Adem Ilkay ; Hanedan, Onur ; Yurdakok, Okan ; Ozyalcin, Sertan ; Kucuker, Seref Alp ; Ozatik, Mehmet Ali</creator><creatorcontrib>Altintas, Garip ; Diken, Adem Ilkay ; Hanedan, Onur ; Yurdakok, Okan ; Ozyalcin, Sertan ; Kucuker, Seref Alp ; Ozatik, Mehmet Ali</creatorcontrib><description>We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P < 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P < 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.</description><identifier>ISSN: 0730-2347</identifier><identifier>EISSN: 1526-6702</identifier><identifier>PMID: 23466929</identifier><language>eng</language><publisher>United States: Texas Heart Institute</publisher><subject>Aged ; Aged, 80 and over ; Aortic Valve Stenosis - diagnosis ; Aortic Valve Stenosis - mortality ; Aortic Valve Stenosis - physiopathology ; Aortic Valve Stenosis - surgery ; Bioprosthesis ; Clinical Investigation ; Female ; Heart Valve Prosthesis ; Heart Valve Prosthesis Implantation - adverse effects ; Heart Valve Prosthesis Implantation - instrumentation ; Heart Valve Prosthesis Implantation - mortality ; Hemodynamics ; Humans ; Male ; Middle Aged ; Multiple Organ Failure - mortality ; Prospective Studies ; Prosthesis Design ; Severity of Illness Index ; Thrombocytopenia - etiology ; Time Factors ; Treatment Outcome</subject><ispartof>Texas Heart Institute journal, 2013, Vol.40 (1), p.50-55</ispartof><rights>2013 by the Texas Heart® Institute, Houston</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568268/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568268/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23466929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Altintas, Garip</creatorcontrib><creatorcontrib>Diken, Adem Ilkay</creatorcontrib><creatorcontrib>Hanedan, Onur</creatorcontrib><creatorcontrib>Yurdakok, Okan</creatorcontrib><creatorcontrib>Ozyalcin, Sertan</creatorcontrib><creatorcontrib>Kucuker, Seref Alp</creatorcontrib><creatorcontrib>Ozatik, Mehmet Ali</creatorcontrib><title>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</title><title>Texas Heart Institute journal</title><addtitle>Tex Heart Inst J</addtitle><description>We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P < 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P < 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aortic Valve Stenosis - diagnosis</subject><subject>Aortic Valve Stenosis - mortality</subject><subject>Aortic Valve Stenosis - physiopathology</subject><subject>Aortic Valve Stenosis - surgery</subject><subject>Bioprosthesis</subject><subject>Clinical Investigation</subject><subject>Female</subject><subject>Heart Valve Prosthesis</subject><subject>Heart Valve Prosthesis Implantation - adverse effects</subject><subject>Heart Valve Prosthesis Implantation - instrumentation</subject><subject>Heart Valve Prosthesis Implantation - mortality</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple Organ Failure - mortality</subject><subject>Prospective Studies</subject><subject>Prosthesis Design</subject><subject>Severity of Illness Index</subject><subject>Thrombocytopenia - etiology</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0730-2347</issn><issn>1526-6702</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkF1LwzAUhoMobk7_guTSm0I-2rTxQpDhVBjsYvNOKEl74ippU5O0sH9vYVP06sA573keeM_QnGZMJCIn7BzNSc5Jwniaz9BVCJ-EEM4ou0SzaSeEZHKO3nd7wFvnmw6vPEDtWrzdrDc4ROiihRBwbEIYAI_KjnCPQXl7wG6IlWshYGUieKycj011jGAPvVUVtNP_Nbowyga4Oc0Fels97ZYvyXrz_Lp8XCc9EyImFOra5JwTLRWw1ORVwbWpTS2pqigpNIAsqEpZZiQRMq-JIUTrlJs0zUBqvkAPR24_6BbqalJ7ZcveN63yh9Kppvx_6Zp9-eHGkmeiYKKYAHcngHdfA4RYtk2owFrVgRtCSTnNBMuFIFP09q_rV_JTKf8G9CB2Pg</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Altintas, Garip</creator><creator>Diken, Adem Ilkay</creator><creator>Hanedan, Onur</creator><creator>Yurdakok, Okan</creator><creator>Ozyalcin, Sertan</creator><creator>Kucuker, Seref Alp</creator><creator>Ozatik, Mehmet Ali</creator><general>Texas Heart Institute</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2013</creationdate><title>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</title><author>Altintas, Garip ; Diken, Adem Ilkay ; Hanedan, Onur ; Yurdakok, Okan ; Ozyalcin, Sertan ; Kucuker, Seref Alp ; Ozatik, Mehmet Ali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-1eddf7330b9ae24f7c83bfdfd91ac108bee981a425f90697d0f00bb43f445e9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aortic Valve Stenosis - diagnosis</topic><topic>Aortic Valve Stenosis - mortality</topic><topic>Aortic Valve Stenosis - physiopathology</topic><topic>Aortic Valve Stenosis - surgery</topic><topic>Bioprosthesis</topic><topic>Clinical Investigation</topic><topic>Female</topic><topic>Heart Valve Prosthesis</topic><topic>Heart Valve Prosthesis Implantation - adverse effects</topic><topic>Heart Valve Prosthesis Implantation - instrumentation</topic><topic>Heart Valve Prosthesis Implantation - mortality</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple Organ Failure - mortality</topic><topic>Prospective Studies</topic><topic>Prosthesis Design</topic><topic>Severity of Illness Index</topic><topic>Thrombocytopenia - etiology</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Altintas, Garip</creatorcontrib><creatorcontrib>Diken, Adem Ilkay</creatorcontrib><creatorcontrib>Hanedan, Onur</creatorcontrib><creatorcontrib>Yurdakok, Okan</creatorcontrib><creatorcontrib>Ozyalcin, Sertan</creatorcontrib><creatorcontrib>Kucuker, Seref Alp</creatorcontrib><creatorcontrib>Ozatik, Mehmet Ali</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Texas Heart Institute journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Altintas, Garip</au><au>Diken, Adem Ilkay</au><au>Hanedan, Onur</au><au>Yurdakok, Okan</au><au>Ozyalcin, Sertan</au><au>Kucuker, Seref Alp</au><au>Ozatik, Mehmet Ali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement</atitle><jtitle>Texas Heart Institute journal</jtitle><addtitle>Tex Heart Inst J</addtitle><date>2013</date><risdate>2013</risdate><volume>40</volume><issue>1</issue><spage>50</spage><epage>55</epage><pages>50-55</pages><issn>0730-2347</issn><eissn>1526-6702</eissn><abstract>We prospectively evaluated the hemodynamic performance of the SORIN Freedom SOLO aortic bioprosthesis, a stentless bovine pericardial valve designed for supra-annular implantation. Forty patients (mean age, 71.68 ± 5.25 yr; 29 men) with severe aortic stenosis underwent aortic valve replacement from January 2008 through August 2009. Patients were evaluated by transthoracic echocardiography and clinical examination, both preoperatively and again at 6 and 24 postoperative months. Peak and mean transvalvular gradients, end-diastolic and end-systolic diameters, interventricular septal and posterior wall thicknesses, indexed volumes of ventricular mass, degrees of aortic regurgitation, and left ventricular ejection fractions were calculated echocardiographically. The valves were implanted with single polypropylene sutures. In the early postoperative period, 1 patient (2.5%) died of multiorgan failure. The mean aortic cross-clamp time was 86.05 ± 34.2 min. Echocardiographic peak gradients were 84.54 ± 16.85 mmHg (preoperative), 29.59 ± 6.27 mmHg (6 mo postoperative), and 24.33 ± 4.67 mmHg (24 mo postoperative) (P < 0.001); left ventricular mass indices were 176.26 ± 39.98 g/m(2) (preoperative), 139.21 ± 30.1 (6 mo postoperative), and 120.51 ± 23.88 g/m(2) (24 mo postoperative) (P < 0.001). During follow-up, the maximum aortic insufficiency recorded was trace, and no valve dysfunctions were observed. Temporary thrombocytopenia was documented in all patients during early postoperative follow-up (lowest level at day 3); recovery to preoperative levels occurred by day 10. The Freedom SOLO aortic bioprosthesis is an easy-to-implant valve with excellent hemodynamic performance. The thrombocytopenia appears to be a transient laboratory finding.</abstract><cop>United States</cop><pub>Texas Heart Institute</pub><pmid>23466929</pmid><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0730-2347 |
ispartof | Texas Heart Institute journal, 2013, Vol.40 (1), p.50-55 |
issn | 0730-2347 1526-6702 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3568268 |
source | PubMed Central |
subjects | Aged Aged, 80 and over Aortic Valve Stenosis - diagnosis Aortic Valve Stenosis - mortality Aortic Valve Stenosis - physiopathology Aortic Valve Stenosis - surgery Bioprosthesis Clinical Investigation Female Heart Valve Prosthesis Heart Valve Prosthesis Implantation - adverse effects Heart Valve Prosthesis Implantation - instrumentation Heart Valve Prosthesis Implantation - mortality Hemodynamics Humans Male Middle Aged Multiple Organ Failure - mortality Prospective Studies Prosthesis Design Severity of Illness Index Thrombocytopenia - etiology Time Factors Treatment Outcome |
title | The Sorin Freedom SOLO stentless tissue valve: early outcomes after aortic valve replacement |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T00%3A34%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Sorin%20Freedom%20SOLO%20stentless%20tissue%20valve:%20early%20outcomes%20after%20aortic%20valve%20replacement&rft.jtitle=Texas%20Heart%20Institute%20journal&rft.au=Altintas,%20Garip&rft.date=2013&rft.volume=40&rft.issue=1&rft.spage=50&rft.epage=55&rft.pages=50-55&rft.issn=0730-2347&rft.eissn=1526-6702&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1315627660%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p266t-1eddf7330b9ae24f7c83bfdfd91ac108bee981a425f90697d0f00bb43f445e9b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1315627660&rft_id=info:pmid/23466929&rfr_iscdi=true |